

# LUMINESCENS<sup>®</sup>

Depigmenting & Brightening Solution



INFORMATION FOR HEALTHCARE PROFESSIONALS ONLY

# LUMINESCENS<sup>®</sup>

A mesotherapy protocol specifically designed for the treatment of skin hyperpigmentation, compatible with all phototypes, oily and dry skin.



## LUMINESCENS<sup>®</sup> Kit

For clinical use



- 1 cream bottle 30 mL
- 2 mesotherapy ampoules x 4 mL each

## LUMINESCENS<sup>®</sup> Home Cream

For outpatient use



- 1 cream bottle 30 mL



## MECHANISM OF ACTION

### Melanogenic enzyme blockers

#### TYROSINASE INHIBITORS

Oligopeptide-34, Tranexamic acid<sup>(1)</sup>, Aminoethyl phosphinic acid & Glycyrrhetic acid, Azelaic acid<sup>(2)</sup>, Arbutin<sup>(3)</sup>, Phenylethyl resorcinol<sup>(4)</sup>, Silybum marianum extract<sup>(5)</sup>, Glabridin<sup>(6)</sup>.

### Melanin formation and transport blockers

#### COPPER CHELATORS AND MC1R ENZYME INHIBITORS

Ellagic acid & Phytic acid, Acetyl tetrapeptide-2, Potassium azeloyl diglycinate<sup>(8)</sup>, Biomimetic peptides, Hexapeptide-40 sh-polypeptide-76 inhibitory, Acetyl hexapeptide-1<sup>(9)</sup>.

### Increase cellular turnover

#### REMOVAL OF PRE-EXISTING MELANIN

Citric acid, Tartaric acid, Salicylic acid, Retinol<sup>(10)</sup>.

### Antioxidants

#### ANTI FREE RADICAL ACTION

Peptide CG-TGP2, Glutathione, Tocopheryl acetate.

# STRENGTHS



Innovative formulation for hyperpigmentation mesotherapy treatment with a patent pending.



No post treatment downtime and no mask needed to be applied for 6-12 hours, unlike other leading products.



No negative impact on daily life.




Cutting-edge formulation, rich in active ingredients, adapted for home treatment with noticeable results with maximum safety and comfort.

## CLINICALLY TESTED RESULTS


Scientifically proven reduction of spots and dermatologically tested.

Study of the effect and cosmetic properties of a product through evaluations and instrumental analysis performed by professionals under medical supervision and consumer self assessments.


IMAGES DETECTED AND ANALYZED WITH MIRAVEX ANTERA 3D®



T0



T28



AU

## BEFORE & AFTER RESULTS

### MICRONEEDLING DEVICES:

DERMA PEN



MULTI-NEEDLE



ELECTROPORATION



FEMALE | AGE 45 | Result after 30 days of treatment



FEMALE | AGE 43 | Result after 60 days of treatment



FEMALE | AGE 32 | Result after 30 days of treatment



FEMALE | AGE 41 | Result after 60 days of treatment

# EVERYTHING WE DO IS AIMED TO IMPROVE PEOPLE'S WELLNESS AND BEAUTY

## About our Company

Over 3.000.000 yearly treatments are performed globally, improving lives and enhancing well-being.

More than 80 countries covered worldwide.

Proudly developed and manufactured in Italy, our products embody the tradition of Italian craftsmanship and excellence.

## R&D dedicated to the aesthetic medicine



## ITALIAN RESEARCH & INNOVATION



**CMed Aesthetics S.p.A.**

Via Panfilo Castaldi, 4 - 56121 Pisa - Italy  
web@cmedaesthetics.com

follow us on:    

[www.cmedaesthetics.com](http://www.cmedaesthetics.com)



LUMBR0ENR2

INFORMATION FOR HEALTHCARE PROFESSIONALS ONLY

1) Tranexamic acid inhibits melanogenesis partially via stimulation of TGF- $\beta$ 1 expression in human epidermal keratinocytes. Xiaoxue Xing 1, Zhongyi Xu 1, Li Chen 1, Shanglin Jin 1, Chengfeng Zhang 1, Leihong Xiang 1. 2) Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. A S Breathnach 1. Affiliations expand • PMID: 8654129. 3) Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Yong Chool Boo. 4) Characterization and topical delivery of phenylethyl resorcinol. Y. Zhang, B. C. Si, C.-P. Kung, J. Hadgraft, M. Heinrich, B. Sinko, M. E. Lane. 5) The treatment of melasma by silymarin cream. Tagreed Altaei BMC Dermatology volume 12, Article number: 18 (2012) Cite this article. 6) The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation T Yokota 1, H Nishio, Y Kubota, M Mizoguchi. 7) Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. Ilgen Ertem 1, Basak Mutlu, Idil Unal, Sibel Alper, Bijen Kivçak, Ozgen Ozer. 8) Maramaldi G, Esposito M. Potassium Azeloyl Diglycinate. Cosm & Toil. 2002;117:3. [Google Scholar] [Ref list]. 9) Up- or downregulation of melanin synthesis using amino acids, peptides, and their analogs. Yong Chool Boo 1,2,3. 10) Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-65.